ABSTRACT
Macrophage recruitment and proliferation of both small vessels (endothelium and pericytes) and fibroblastmyofibroblasts are the fundamental and provisional cellular findings in repair through granulation tissue (RTGT).Endothelium and pericytes of preexisting microvasculature may act as progenitor cells of new endothelial cells and new pericyte-fibroblastmyofibroblasts, respectively.Likewise, fibroblasts may be progenitors of themselves, and of myofibroblasts and pericytes. Moreover, all these cells may originate from circulating progenitor cells or other progenitor cells..According to this extensive cellular plasticity, this work reviews the adult stem cells (ASC) and transitamplifying cells (TAC) related to the principal cellular components of RTGT.Moreover, we hypothesize that the perivascular region, with a heterogeneous pericyte-like cellular population, including pericytes, perivascular fibroblasts and homing cells from the bone marrow (fibrocytes and bone marrow mesenchymal cells), is the niche of progenitor cells in RTGT and the substrate of regulatory mechanisms (perivascular niche hypothesis).We also highlight RTGT as a "paracrine transitional organ" during involutive phenomena and cellular differentiation.Furthermore, we consider the combined role of both systems (ASC-TAC and RTGT) in tissue engineering and in pathological processes, such as fibrosis, organization, atherosclerosis, and tumor stroma.
3.REGIONS WITH RTGT CAPACITY
The regions with RTGT capacity are the most ubiquitous in all repair.However, they have a common characteristic: the presence, in or near, of an active preexisting pericytic microvasculature, where the repair phenomena initiate.The latter originate above all in the venous side of the circulation, specifically in the postcapillary venules (37, 38).Therefore, this microvasculature forms part of a substrate of a general inflammatory-reparative system in which the vessels not only intervene in recruitment of inflammatory cells and in new capillary formation (angiogenesis), but they may also contribute matrix-forming cells (fibroblasts-myofibroblasts, osteoblasts, chondroblasts), and contractile and adipose cells.Vessels of greater caliber in the circulation, such as the rat femoral vein, with a discontinuous internal elastic lamina and smooth muscle cells in their media layer, are also capable of contributing to RTGT (39-42).
The RTGT capacity of the regions has biological and clinical implications.In avascular tissues (e.g.cartilage and cornea), there is capacity of regeneration, but RTGT may only originate from neighbouring vascularized tissues.In this case, the intensity of RTGT component penetration into an avascular tissue depends on the properties of the latter (e.g.inhibitory action of antiangiogenic substances, as occurs in cartilage).In addition, the RTGT characteristics of a region may be conditioned by its regenerative capacity (interactions between regeneration and RTGT).For instance, in the central nervous system and cardiac muscle, where the regeneration is limited, the RTGT local precursor cells are generally involved in scar tissue replacement.
EVENTS IN RTGT
RTGT is a complex biological process that involves coagulation, inflammation, angiogenesis, proliferation of mesenchymal cells, vascular involution and remodelling.Despite the continuous and ordered nature of the process, these findings occur in several overlapping phases, according to predominant mechanisms.
INFLAMMATORY PHENOMENA ASSOCIATED WITH RTGT, WITH PARTICULAR REFERENCE TO RECRUITMENT OF CELLS AND RELEASE AND MOBILIZATION OF GROWTH FACTORS
An inflammatory response, with vascular dilatation, increased vascular permeability, and diapedesis of leukocytes may precede and accompany the RTGT.Indeed, the association of several inflammatory cells of hematopoietic origin (hematopoietic stem cells) with the RTGT is a well-known fact (43-48).The cells that accumulate within the lesion compartment include neutrophils, lymphocytes, mast cells and macrophages.Between 1 and 6 h, the PMNs predominate.Thereafter, the number of monocytes/ macrophages increases, while the number of PMNs decreases dramatically.Several inflammatory mediators, such as vasoactive mediators and chemotactic factors, participate in these phenomena (49).Indeed, the signaling factors that begin the repair process, with intervention in inflammation and recruitment, migration, proliferation and differentiation of progenitor cells, include granulocyte colony-stimulating factor (G-CSF), granulocyte-monocyte colony-stimulating factor (GM-CSF), stem cell factor (SCF) 06), stromal cell-derival factor-1 (SDF-1), tumor necrosis factor-α (TNF-α), interleukin-8 (IL-8), erythropoietin (EPO), interleukin-10 (IL-10) and vascular endothelial cell growth factor (VEGF).Therefore, numerous intercellular signaling pathways mediated by surface adhesion molecules and cytokines intervene in the initial phases of the RTGT.To this is added mobilization, by proteinases secreted by inflammatory cells, of factors stored in the heparin-like glycosaminoglycans of extracellular matrix, such as TGF-β, FGF2 and VEGF (50, 51).
6.STEM CELLS AND RTGT
Overlapping with the inflammatory phenomena and cell recruitment, the formation of granulation tissue is initiated, and macrophages, vascular sprouts and fibroblasts progressively appear in the interstitium and move at the same time (52) between a provisional matrix, including fibrin, fibronectin and hyaluronic acid (53-55).Thereafter, concomitant proliferation of fibroblast/myofibroblasts and capillaries originates a highly vascularized granulation tissue, in which many different types of mesodermal stem cells, including endothelial precursor cells and multipotent adult precursor cells, may participate, which may even originate other cell lineages, such as chondroblasts, osteoblasts and preadipocytes.Bearing in mind the above, recruited inflammatory cells (macrophages, mastocytes, neutrophils and eosinophils), endothelial cells and mesenchymal cells, including, among others, matrixforming cells (fibroblasts-myofibroblasts, chondroblasts and osteoblasts), preadipocytes and precursor of arterial myointimal cells intervene in tissue undergoing repair and in maintenance of injured tissues during postnatal life.The mesenchymal cells can be tissue-derived stem cells and/or peripheral blood pluripotent stem cells (circulating progenitor cells), which form part of a system (for review, 29) comprising adult stem cells (ASC) and transitamplifying cells (TAC), as well as the ASC niches, with their intrinsic and extrinsic regulatory mechanisms.Following, we will consider the progenitor cells related to the principal cellular components of this initial tissue: macrophages, vascular cells (endothelium and pericytes) and fibroblast-myofibroblasts.
Macrophages and progenitor cells
Macrophages that help remove damaged cellular and extracellular debris, with the capacity to release numerous cytokines (vascular endothelial growth factor, platelet derived growth factor, α and β transforming growth factors, basic and acidic fibroblast growth factors, heparinbinding epidermal growth factor) play a pivotal role in inflammation and repair (56).The origin of macrophages from bone marrow-derived peripheral blood monocytes has been accepted traditionally (57, 58).Admittedly, along with the bone marrow progenitors and blood monocytes, they form part of the mononuclear phagocyte system (59, 60).Thus, predominantly in the initial phase of RTGT, monocytes are observed adhering to the endothelium of the parent vessels ( Figure 1A and 1B), as well as passing through the endothelial junctions ( Figure 1C The replacement and renewal of macrophages principally occur from monocyte recruitment.Recently, it has been found that a significant local proliferation (59, 60) and presence of tissue proliferating monocyte-like cells (61) are also involved in the replacement and renewal of macrophages.
Association between macrophages and other cells, such as endothelial cells, pericytes and fibroblast/myofibroblasts, is morphologically evident during RTGT ( Figure 2D ), suggesting interactive cooperation in migration, differentiation and functional activity.
Certain similarities between stem cells/progenitors and macrophages have been pointed out.Indeed, stem and progenitor cells share some characteristics of macrophages (62).For instance, adipocyte progenitors have certain phagocytic activity, and they can phagocytize microbes and apoptotic bodies (63, 64).Likewise, preadipocytes and macrophage phenotypes (Fig.1A) and of a postcapillary venule (Fig.1B) , as well as passing through the endothelial junctions (Fig.1C and 1D .arrows). (Uranyl acetate and lead citrate, x15000).In Fig.1A a detail of the adherence is shown in the lower insert.The upper inserts correspond to semithin sections (Toluidine Blue, x1150) are very similar, and conversion of preadipocytes to macrophages has been described (65).
Regarding their contribution of other cellular components to RTGT, certain subpopulations of monocytes /macrophages may acquire endothelial properties in angiogenic conditions (66-74), and they have been observed organizing cell columns (tunneling) in vitro (75) and in vivo (75-78), suggesting that these cords could evolve into capillary-like structures (79, 80).In this way, monocytes / macrophages may also contribute to the control and regulation of neovascularization (75), enabling 
. Preexisting endothelium as progenitor cells
Preexisting endothelium has been considered as the principal progenitor of new endothelium in angiogenesis.The latter is the neovascularization or formation of new blood vessels from the established microcirculation by a process of sprouting from preexisting vessels.The growth factors that activate endothelial cells (EC) include vascular endothelial growth factor and basic fibroblast growth factor, produced by macrophages and fibroblasts, among others.The events classically described during capillary growth in vivo include (38): a) EC and pericyte activation; b) degradation of the basal lamina of preexisting vessels by EC (proteolytic destruction of the extracellular matrix); c) EC migration from preexisting vessels towards the angiogenic stimulus; d) EC proliferation; e) migration and proliferation of pericytes from preexisting vessels; f) formation of a new capillary vessel lumen (vascular tube formation); g) appearance of pericytes around the new capillaries; h) changes in extracellular matrix with development of a new basal lamina; i) capillary loop formation; j) early changes in the newly-formed vessels (persistence, involution and differentiation); and k) capillary network formation and eventually organization of larger microvessels.Traditionally, it has been considered that blood vessels grow by means of a movement of EC (98).This fact of EC migration is currently considered an important step during angiogenesis (99) and is directionally regulated by chemotactic, haptotactic and mechanotactic stimuli.In the initial phase of neo-vascularization, the EC degrade the vascular basement membrane of the parent vessel, protrude through its wall and begin to migrate into the interstitial space towards the angiogenic stimulus ( Figure 3A ).This mechanism involves macrophage angiogenic factors, which stimulate plasminogen activator and procollagenase release by the endothelial cells, with basement membrane degradation by proteases (plasmin and collagenase).Most researchers agree that these changes precede endothelial replication in such a way that migration and mitoses are independent phenomena (100-102).In other words, angiogenesis begins with pseudopodia of migrating EC ( Figure 3A ) and progresses to the proliferation of these cells (103-107).Therefore, angiogenic stimuli may operate through chemotaxis, and EC mitosis may be a secondary event (100, 101,108).When the entire EC migrates into the interstitium, other EC follow and loose EC sprouts or cords are formed in the perivascular stroma ( Figure 3B and 3C).Mature endothelial cells, normally in a resting state, show an extremely slow turnover rate (109-112) of 2 months or more.Thus, using 3HThymidine, the labeling index is lower than 1% in normal capillary and venular EC of the retina, liver (113), myocardium, stomach (113), striated muscle (113) and skin (113-116).For example, it is 0.0.1 % in capillary EC in the adult rat retina.Since the turnover rates of EC are extremely low, angiogenesis is generally a quiescent process in the healthy adult organism (117).Nevertheless, the EC can quickly convert to a proliferative state during angiogenesis and in several related processes, such as endothelium repopulation in organ transplants, repair of large vessel defects and thrombi recanalization (115, 118).However, EC proliferation is not essential, since angiogenesis has been shown to take place even in the absence of EC replication (119).During angiogenesis, endothelial DNA synthesis occurs in parent vessels before sprouting and according to some authors as early as 6 to 8 hours after an angiogenic stimulus is applied (115).The increase of the turnover rate of EC can be considerable ( Figure 3D ).For example, the 3 H-Thymidine labeling index of EC increases to 9% in tumors (120).The time and the exact site of EC division are controversial.For some investigators, EC mitosis appear concomitant with sprouting (119), while most authors are of the opinion that EC begin in mitosis after they start to migrate.The EC mitosis appears in both the parent vessels ( Figure 3E ) and the newly formed vessels.In the latter, it has been pointed out that they occur at the tip (43, 121), but it is accepted that when capillary sprout budding begins, endothelial proliferation takes place in cells following the "leader EC" (Figure 3E ), but not usually at their tips.In other words, the zone of replication is closer to the parent vessel (99, 108, 122-124).The ability of angiogenic stimuli to induce (Fig.3A, arrow) and when the entire EC migrates into the interstitium other EC follow, originating loose sprouts or cords in the perivascular stroma ( Fig.3B and 3C -arrows) .A considerable increase of 3 H-thymidine labeling is observed in EC (Fig.3D -arrows) and in perivascular cells (Fig.3D -arrowheads) . Fig.3E shows a mitosis (M) in an EC of a parent vessel following the "leader" migrating ECs, which originate a cord in the perivascular stroma (arrow). (183) (184) (185) (186) (187) (188) (189) (190) , such as fibroblasts (47, 191) , chondroblasts (192) , osteoblasts (193) (194) (195) (196) , preadipocytes (191, 197) , vascular smooth muscle cells and myointimal cells (198, 199) .In the initial phases of RTGT, the pericytic microvasculature undergoes a sudden, brief and intense pericyte proliferation (37).In this way, autoradiographic studies show an increased amount of label in pericytes of postcapillary venules and capillaries ( Figure 3D ) (37, 101, 114, 115, 200, 201) .Besides, sequential morphologic findings in the pericytes during the initial phase of granulation tissue formation agree with the hypothesis that pericytes may be an important source of new fibroblasts (129, 183).These sequential morphologic findings include: a) the pericytes, bulging from preexisting vessels, shorten their processes and increase their somatic volume ( Figure 2B and 2C and 4B); b) the nuclei contain prominent nucleoli and their cytoplasms show numerous ribosomes, either singly or in aggregates ( Figure 2B and 2C); c) multiple profiles of rough endoplasmic reticulum are observed ( Figure 2B and 2C); d) the pericyte basal lamina is frequently disrupted and fragmented; and e) numerous pericytes project into the extravascular space, appear detached from the vessel walls and adopt transitional cell forms between themselves and fibroblast-like cells ( Figure 2D ) (37).As mentioned above, the migrating monocytes contribute to the detachment and mobilization of the activated pericytes in the pre-existing pericytic microvasculature ( Figure 2A , 2B and 2C).
Using Monastral Blue as a tracer for labeling cells in the walls of pericytic microvasculature, the marker was first observed in pericytes ( Figure 4A ) and subsequently in pericytes bulging from preexisting vessels ( Figure 4B , 4C and 4D), and in fibroblast-myofibroblasts ( Figure 4E and F) during granulation tissue formation (37), as well as in chondroblasts (202) (Figure 4G ), osteoblasts ( Figure 4H ) (195) and myointimal cells after specific induction (203, 204) .
Moreover, cells specifically expressing known markers of pericytes also express markers characteristic of stem cell population (205) .Endosialin, which may be a marker of mesenchymal stem cells, has been identified in activated myofibroblasts and pericytes (206, 207) .Mesenchymal stem cell populations have been described residing in the microvasculature of the tissue origin (perivascular niche) (29, 37, 183, 189, 192, 199, (208) (209) (210) (211) .Thus, the majority of dental pulp stem cells express pericyte associated antigen (208) and co-express Notch 3 (regulating stem cell fate specification) and RgsT (marker for pericytes) (209) , suggesting a perivascular niche of postnatal mesenchymal stem cells.Likewise, a population of multipotent CD34-positive, adipose stromal cells shares pericyte (chondroitin sulfate proteoglycan, CD140a and CD140b) and mesenchymal (CD10; CD13 and CD90) surface markers (212).Although the mechanisms controlling pericyte differentiation are poorly defined, Wnt/beta-catenin signaling stimulates chondrogenic and inhibits adipogenic differentiation of the pericytes (213).
In soft tissue lesions, some authors consider pericytes as the progenitor cells of several pseudosarcomatous processes (214, 215), malignant fibrous histiocytoma (216) and mixoid liposarcoma (217) .Pericytes and endothelial precursor cells are also important participants among the many cells that give rise to progressing malignant disease (218).
Other pericyte precursors (pericytes as descendent cells)
Recruitment of pericytes to newly formed vessels from fibroblast and bone marrow progenitor cells has been described (these progenitors will be considered in sections 6.3.1. and 6.3.2.Here we present the controversy about the participation of the bone marrow in pericyte and endothelial cell origin).
Although bone marrow progenitor cells can be recruited during the formation of new vessels and vasculature, remodelling (219) (220) (221) , there is controversy about their participation in pericyte and endothelial cell origin.As mentioned above, using neovascularization models, several authors point out those BM-derived precursors give rise to endothelial cells (146, 150, 222-224); while others have proposed that bone marrow, precursor cells only develop pericytes but not endothelial cells (219) (220) (221) .Recently, it has been indicated (221) that new corneal vessels have a dual source: bone marrowderived precursor cells (53% of all neovascular pericytes) and pre-existing limbal capillaries (47% of all neovascular pericytes).Of the bone marrow-derived pericytes, 96% expressed CD45 and 92% CD11b, which suggested their hematopoietic origin.Using mouse chimera in brain repair after ischemia (225) , two populations of bone marrowderived cells were observed: one in the brain parenchyma (predominantly microglia) and another associated with remodeling blood vessels in perivascular location.The latter were negative for endothelial cell markers, but expressed desmin and were immunoreactive for angiogenic factors, endothelial growth factor and transforming growth factor beta, suggesting pericytes.Mobilization and recruitment of bone marrow-derived pericyte progenitor cells have also been described in tumors (219, 226, 227) .Evidence that mature vessels develop from pericyte/macrophages networks and that almost all macrophages and more than half of the pericytes derived from the bone marrow have been shown using subcutaneous matrigel plugs (81).By contrast, only 10% of endothelial cells exhibit a bone marrow origin (81).
Pericyte progenitor cells have been described from non-endothelial mesenchymal cells isolated from the rat aorta.The latter, cultured in a serum-free medium with fibroblast growth factor, proliferated slowly and formed spheroidal colonies, expressing CD34, Tie-2, NG2, nestin and PDGF α and β receptors.When cocultured in collagen with isolated endothelial cells, they transformed into pericytes (228).
Fibroblast/myofibroblasts, ASC and TAC
The origin of the heterogeneous population of fibroblast/myofibroblasts, which respond to mediators of inflammation and intervene in the integrity of the tissues, and in the production (matrix-synthesizing cells), deposition and degradation (matrix-degrading cells) of extracellular matrix proteins, in contraction (myofibroblasts) to reduce the size of the wound, in growth we will consider the fibroblasts as precursor or descendent cells.
Preexisting fibroblasts as precursor cells
A conventional hypothesis is that local relatively quiescent fibroblasts around the injured tissue migrate, proliferate and originate the new activated fibroblasts and myofibroblasts, with extracellular matrix protein production and wound contraction (233) (234) (235) .Therefore, fibroblasts, normally involved in their quiescent state in slow turnover of the extracellular matrix (primary producers of type I, III and V collagen and fibronectin, contributors of the basement membrane by secretion of laminine and type IV collagen, and with remodelling capacity by means of fibroblast-derived matrix metalloproteinases) undergo a change in phenotype to a proliferative, synthetic ( Figure 5A ) and contractile state (myofibroblasts) ( Figure 5B ) (236) .Indeed, in the margin of lesions, the resting fibroblasts proliferate, express integrin receptors (that bind fibronectin and fibrin on fibroblasts -55, 237), migrate (by means of an active fibroblast-derived proteolytic system, including collagenases, gelatinase A, plasminogen activator and stromelysin -238, 239) and differentiate into myofibroblasts, with extracellular matrix protein production (240, 241), secretion of growth factors and chemotactic factors, migration, contraction (production of alpha smooth muscle actin) (235) and parenchyma interactions (dynamic cross-talk between fibroblasts and parenchyma cells).The myofibroblasts temporarily acquire their expression of α-smooth muscle actin, which disappears progressively (between 15 and 30 days).It is generally accepted that collagen deposition continues long after myofibroblasts decline.Therefore, myofibroblasts are temporarily activated before collagen producing fibroblasts (232) .Growth factors, such as transforming growth factor β1 (242) and platelet derived growth factor (243), contribute to activate the local fibroblasts.In this way, other cells may influence their proliferation, differentiation, extracellular matrix synthesis and survival.For instance, adipose-derived stem cells have the capacity to promote human dermal fibroblast migration, proliferation, and secretion by cell-to-cell direct contact and by paracrine activation through secretory factors, such as PDGF, insulin-like growth factor, bFGF, TGF-β, HGF and VEGF (244).As mentioned above, endosialin, a marker of mesenchymal stem cells, is expressed by myofibroblasts and pericytes (206) .
Induced pluripotent stem cells (IP cells) can be generated from adult human fibroblasts (245) .Indeed, cells similar to human embryonic stem cells in morphology, proliferation, surface markers, gene expression, promoter activities, in vitro differentiation, telomerase activity and teratoma formation were generated from adult human fibroblasts by retrovirus-mediated transfection of four transcription factors: Oct3/4, Sox2, c-Myc and Klf4 (245) .Therefore, IPS cells can be derived from somatic cells and may thus lead to important drug discoveries and advances in regenerative medicine (246).
Other fibroblasts/myofibroblasts precursors (fibroblasts/myofibroblasts as descendent cells)
Although RTGT fibroblast/myofibroblasts originally derive from resident tissue fibroblasts in the proximity of the RTGT (55, 237), this possibility does not preclude that pericyte, bone marrow derived cells or other transdifferentiated cells contribute to their heterogenous fibroblast/myofibroblast population (247) .The origin from pericytes has been previously considered (section 6.2.2.1.).The bone marrow precursors, bone marrow mesenchymal cells and fibrocytes, will be discussed below.
Since 1970, fibroblast colony formation from monolayer cultures of bone marrow and blood cells (fibroblast colony-forming units) has been demonstrated (248) (249) (250) (251) , evidencing a bone marrow origin for fibroblasts.A rare cell within human bone marrow mesenchymal stem cell culture (multipotent adult progenitor cells or MAPCs) has been identified (148, [251] [252] [253] and immature mesenchymal cells derived from the bone marrow appear to be constantly repopulating normal and injured connective tissues (254) (255) .In general, bone marrow mesenchymal AS cells are located in the complex system of the bone marrow stroma (bone marrow stromal cells), and they can be isolated by means of Stro-1+ antibody recognition (256, 257) .These cells have the capacity to differentiate into mesenchymal lineage cells and, with appropriate environmental conditions into cells of different embryonic origin, such as cells with visceral mesoderm, neuroectoderm and endoderm characteristics.In other words, these cells have high capacity of transdifferentiation and plasticity (20, (258) (259) (260) .Indeed, the bone marrow mesenchymal cells may differentiate phenotypically into adipose, cartilage, bone, vascular smooth muscle, skeletal and cardiac muscle, hepatocytes, neural elements and hematopoietic-supportive stromal cells (6, 9, 15, 17, 147, [260] [261] [262] [263] [264] [265] [266] [267] [268] .Epidermal growth factor is considered as a candidate for ex vivo expansion of bone marrow-derived mesenchymal ASC (269) .Transcription factors, which regulate the expression of the differentiation genes of the aforementioned cells, participate in this differentiation process.For example, C/EBP and PPARγ families and other transcription factors intervene in adipocyte (270, 271) and Cbfa1/Runx2 in osteocyte (272, 273) differentiation.Besides, there are regulation control mechanisms such as hormones and growth factors.Using bone marrow mesenchymal ASC, alveolar bone cells and periosteal cells for tissue-engineered bone formation, it has been demonstrated that the periosteal cells originate approximately double the amount of newly formed bone than bone marrow mesenchymal cells (274) .Other sections of this work describe the role of transplanted bone marrow cells in organ and solid tissue regeneration.
A bone marrow-derived circulating population of mesenchymal progenitors, termed "fibrocytes" (275) (276) (277) (278) (279) or "fibrocyte precursors", which rapidly enter sites of tissue injury, was identified a decade ago (275) .Subsequent studies have demonstrated that these cells express markers of leukocytes (CD45, LSP1), monocyte lineage (CD11a, CD11b, CD13, CD32, CD64), as well as hematopoietic stem cell/progenitor antigens (CD34, CD105) and fibroblast products (collagen I and III, fibronectin, vimentin MMP9) (275) (276) (277) (278) (279) (280) (281) (282) (283) (284) (285) (286) (287) (288) .Adherent cultured fibrocytes develop a spindle-shaped morphology (275) and express MHC, class II and co-stimulatory molecules (CD80 and CD (Fig 5A) and myofibroblasts ( Fig 5B) during granulation tissue formation.The rough endoplasmic reticulum is well developed in both.A bundle of cytoplasmic microfilaments (arrow) with dense bodies is observed in a myofibroblast.Transmission electron photomicrographs (Uranyl acetate and lead citrate, x15000). 86).Recently, it has been pointed out that CD34+ fibrocytes, which are present in the connective tissue of virtually all human organs, derive from circulating CD14+ monocytes (289) .These cells secrete numerous cytokines and have the property of expressing smooth muscle actin, while retaining CD34 expression, when they acquire myofibroblast-like differentiation (277) .These cells have the ability to present antigen in vitro and in vivo (276, 280, 290) , and cultured fibrocytes in vitro and in vivo facilitate angiogenesis by means of proteolysis of the basal lamina (secretion of active matrix metalloproteinase 9-MMP-9) and by secretion of growth factors, such as VEGF, β FGF and PDGF (291).As we shall see below, fibrocytes intervene in development of fibrotic lesions, connective tissue disease, atherosclerosis and in tumor stroma formation.On the other hand, the use of marrow-derived stem cells as a therapeutic procedure has been considered, for instance, to accelerate healing in chronic ulcers (292).
An immunosuppressive effect on adult dendritic cells differentiated from CD 34+ hemopoietic progenitor cells has been contributed, suggesting that mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway (293).
Another postulated origin is that epithelial cells undergo epithelial to mesenchymal transdifferentiation (see below).
INVOLUTIVE PHENOMENA.RTGT AS A "PARACRINE TRANSITIONAL ORGAN"
Several components of the granulation tissue undergo involution, which is highly evident in the newly formed vessels.Indeed, angiogenesis ceases and most of the endothelial cells disintegrate drastically because of apoptosis, only persisting the preferential vasculature.In this mechanism intervene antiangiogenesis factors (angioprotein, angiostatin and endostatin) (294) and thrombospondins 1 and 2, among other matrix molecules (295).At first, the numerous disintegrating vessels show marked intravascular accumulation of factor-releasing platelets (platelet thrombus) ( Figure 6A , 6B, 6C, 6D and 6E), and the granulation tissue becomes a "paracrine transitional organ".Subsequently, homogenized platelets, endothelial cell debris and basal membrane residues are observed ( Figure 6F , 6G and 6H).The fibroblasts acquire myofibroblast phenotype, with cytoplasmic actincontaining filaments and cell-matrix and cell-cell linkages (296), intervening in tissue contraction, collagen synthesis and catabolism of collagen in combination with matrix 
RTGT AND CELLULAR DIFFERENTIATION, DEDIFFERENTIATION, TRANSDIFFERENTIATION AND FUSION
As mentioned above, the putative cells with the capacity to originate myofibroblasts during RTGT, such as fibroblasts, pericytes and marrow stromal cells, can give rise to other cell lineages and differentiate "in vitro" and "in vivo" into osteoblasts ( Figure 4H ), chondroblasts ( Figure 4G ), preadipocytes (Figure 7 ), or smooth muscle cells by means of growth factors and specialized induction (183, 195, 202, 204, (298) (299) (300) (301) (302) (303) (304) (305) (306) (307) .This generalized system may complete the repair from locally resident mesenchymal cells that provide tissue-specific progeny, such as adipose, muscle, periostium, trabecular bone, synovium and dermis- In Fig.7C , the adipoblast appears enveloped by a long thin process of a pericyte (P).In Fig.7D derived mesenchymal cells (195, 303) .Furthermore, these mesenchymal cells are highly plastic and they may also produce progeny of endodermal and ectodermal lines (20, 258, 271, 308, 309 16, 311-315) .Finally, cell fusion may occur, although it seems to be biologically irrelevant for its extreme rarity (316), except for macrophages, which are able to fuse among themselves and with other cell types (317). (318) (319) (320) (321) .In adult life, the repair process reproduces these interactions between regenerative elements (parenchyma) and RTGT components (stroma).In this way, RTGT lend the regenerative parenchyma morphofunctional support and facilitate a multistep mechanism, involving angiogenesis and organization by recruitment of fibroblast-myofibroblasts and by producing and remodeling extracellular matrix components.For instance, in skin wounds, fibrin clot forms a provisional scaffold for cell migration, proliferation and differentiation.In tissue engineering, parenchyma-stroma interactions similar to RTGT appear to be essential and they may play an active and instructive role in programming the final tissue structure and function.In other words, it is necessary to develop prototype tissue engineered matrices to support the simultaneous growth of different cell types (322) and a rapid induction of angiogenesis (322) (323) (324) (325) (326) (327) .The strategies in tissue engineering may utilize: a) cell suspensions or cell-sheets, b) biomolecules, c) matrices in combination with cells and/or biomolecules, and d) 3-D environments or scaffolds with seeding and culturing specific cell types (328) .The scaffolds for tissue engineering should have several properties, such as degradability, biocompatibility, non-immunogenicity, easy reproduction and the possibility to incorporate and deliver bioactive molecules (growth factors, peptides, lyophilized cell fractions, etc.).Among these conditions are the mechanical properties, since stiff or soft scaffolds may be used.For instance, the latter are more suitable for adipose tissue engineering (329, 330) .In addition, in these strategies, it is fundamental to promote regeneration and repair.Indeed, optimum procedures, combining scaffolds, cells and/or biomolecules, should be capable of inducing adhesion, migration, proliferation, differentiation, angiogenesis and production of new extracellular matrix, in a manner similar to that which occurs during regeneration and RTGT, in which the process results in the formation of new structures that reproduce the original morphology and function.
ASC, RTGT AND TISSUE ENGINEERING
Future directions of research in tissue engineering include the development of multi-tissue organs, imitating what occurs during embryonic development and in adultlife repair processes.Indeed, in embryonic development, a bidirectional molecular dialog between parenchymal cells and stromal cells is necessary for normal organ development and function
ASC AND RTGT IN PATHOLOGY

ASC, Organization, abnormal RTGT and Fibrosis
Examples of organization are the creation of new masses of fibrous tissue in blood clots or inflammatory exudates with fibrin deposits through granulation tissue (331) .Thus, organization of thrombus initiates with leukocyte and macrophage infiltration (inflammatory stage), followed by neovascularization, and fibroblast/myofibroblast proliferation (proliferative stage) and progressive collagen deposition and contraction, while myofibroblasts decline (contraction stage) (332) .To this can be added microvascular involution, persistence of preferential vessels and recanalization.Monocytes/macrophages play a central role in thrombus organization (333) .For example, the gene for a chemokine link to macrophage activation CXCL14 is upregulated (332) .
Abnormal RTGT may occur by defect or excess.An example of deficient RTGT are diabetic ulcers, in which ASC descendents are modified in their proliferation, differentiation and functional activity, with impaired neovascularization, increasing levels of proteinases and decreasing synthesis of collagen.Several factors are involved in these modifications, such as vascular disease with subsequent ischemia (anoxia and reducing nutrients), impaired granulocytic chemotaxis and function with infections and prolonged inflammation, associated neuropathy and defective macrophage function (334, 335) .
Examples of excessive RTGT are hypertrophic scars and keloids with higher collagen production in which several factors intervene, such as increased and exaggerated responses to fibrogenic cytokines (enhanced expression of TGF-β, mRNA (336) , mutations in regulatory genes and abnormal epidermal mesenchymal interactions -337, 338-).Fibrocytes also contribute to the fibroblast population in these lesions (281, 339) .
Examples of fibrotic lesions are idiopathic pulmonary fibrosis and systemic fibroses in which an important contribution of bone marrow-derived cells in the early stages has been pointed out (276, 287, 288, (340) (341) (342) (343) .Evasion of myofibroblasts from immune surveillance has been proposed as a mechanism for tissue fibrosis.Indeed, this mechanism may occur since myofibroblasts possess Fas/Fasl-pathway-dependent characteristics that allow them to escape from immune surveillance and resulting organ fibrosis (345) .Recently, transformation of microvascular endothelial cells into myofibroblasts has been considered as having a potential role in the etiology and pathology of fibrotic disease (136, 346).
ASC, RTGT and atherosclerosis
In atherosclerosis, as in RTGT, inflammatory phenomena precede and accompany the process, quiescent cells are induced to proliferate rapidly, new blood vessels are formed, stromal cells migrate, the extracellular matrix is invaded, the new tissue is remodeled and the same factors initiate and regulate the process.In this way, the cellular events in the formation of atherosclerotic lesions after injury include regeneration of endothelial monolayer, infiltration of monocyte cells and myointimal cell proliferation (347) .The regeneration of the endothelial monolayer may have the same sources as those previously described for neovascularization, namely, by migrating and proliferating preexisting neighbouring endothelial cells or by circulating progenitor endothelial cells (bone marrowderived cells expressing CD133 or CD34 -137, 139, 142-)(see above).
The traditional hypothesis is that myointimal cells in atherosclerotic lesions are derived from the medial smooth muscle cells (348) (349) (350) (351) , which migrate from the media into the intima, acquiring a synthetic phenotype with matrix synthesis.This hypothesis is now shrouded in doubt and the myointimal cell origin remains the subject of ongoing debate, since myointimal cells may be considered from a variety of sources (352) .Indeed, the following possibilities may be considered: arterial media layer origin (SMCs and SMC related cells), adventitial progenitor cells and bone-marrow-derived circulating cells.
The hypothesis of arterial media layer SMC origin (348, 349, 351, (353) (354) (355) (356) (357) (358) (359) (360) (361) (362) (363) (364) (365) is based on the following: a) the cells present in the intimal thickening (myointimal cells -neointimal SMC cells) correspond in appearance to smooth muscle cells (348, 354, 355, 357-360, 362-364, 366) , b) these myointimal cells show the same early enzymatic reaction as cells of the innermost third part of the media layer (356, 361) , c) muscle cells from the media layer have been observed crossing the "gaps" of the internal elastic lamina, suggesting a capacity to move through this membrane (354, 357, 363, 366) , and d) tritiated thymidine incorporates in the internal zone of the media layer, prior to appearing in the intimal layer (353, 367) .Nevertheless, differences between media and neointimal SMC cytoskeletal features, growth pattern, responses to growth factors /cytokines and matrix synthesis/degradation have been described (368) .An origin of myointimal cell from a preexisting and distinct subpopulation of the media layer SMC has also been pointed out (369) .
The hypothesis of adventitial progenitor cells (199, 203, 204, (370) (371) (372) (373) (374) (375) (376) is based on the following: a) In autoradiographic studies on the incorporation of 3 Hthymidine, during intimal thickening developing in occluded arterial segments, DNA synthesis was first seen in the adventitia, fundamentally in the vasa-vasorum pericytes, later in the adjacent media and subsequently in the intimal thickening (Figure 8A , 8B and 8D) (199) , with contribution of myofibroblasts to neointimal formation (377) .Coronary adventitial fibroblasts display proliferation, collagen synthesis and phenotypic heterogeneity in response to stimulation, whereas medial SMCs maintain a highly differentiated phenotype (371) .Abundant progenitor cells expressing stem cell markers (Sca-1; C-kit; CD-34 and FlK-1) are present in the adventitia (372, 374) and can differentiate into myofibroblasts, migrate to arterial media or intima layers and differentiate into SMCs (372, 374, 376) .Sca-1+ cells obtained from explanted cultures of adventitial tissues and transferred to the adventitial side of vein grafts were found in atherosclerotic lesions of the intima (372) .The adventitia may contribute progenitor cells from the interstitium (fibroblasts) or from the vasavasorum.When human vascular adventitial fibroblasts were cultured in appropriate media, they showed myogenic differentiation, with increased expression of smooth muscle actin and calponin (378) .Regarding vasa-vasorum, microvessel penetration into the arterial wall from the adventitial layer has been observed in atherosclerosis, not only in its later stages, but also in the earliest stages of its precursor lesions, such as intimal thickening (Figure 8C , 8E, 8F, 8G, 8H, 8I and 8J) (41, 199) .This initial response may be considered as a particular form of granulation tissue formation and is followed by a rapid microvascular involution.In this way, it has been postulated that arterial intimal thickening results from a similar mechanism to that of the organization of thrombus, with subsequent events depending on whether or not the arterial circulation has been interrupted.On interruption, there is both a penetration of the vasa-vasorum and a myointimal differentiation from the adventitial recruited cells (pericytes, fibroblasts or circulating progenitor cells), whereas when the arterial circulation has remained unchanged there is no vasavasorum penetration and the intimal thickening originates from recruited cells migrating from the arterial vasavasorum and adventitia (199, 204) .Using a technique that specifically labels venules, predominantly postcapillary venules, in addition to recruited macrophages, newly formed endothelial cells and a supplementary population of fibroblast-myofibroblasts and myointimal cells were contributed from the periarterial microvascularization during arterial intimal thickening formation (204) .The fibroblasts and the vasa-vasorum pericytes are the principal candidates in adventitial participation in the arterial myointimal cells (199, 372, 374, 376) .The aberrant differentiation of pericytes may contribute to the development and progression of atherosclerosis and calcific vasculopathies (213).
The hypothesis of bone-marrow-derived circulating cells is based on the presence of marrow stromal cells as stem cells for non-hematopoietic tissues (379) and on the discovery of circulating fibrocytes as collagenproducing cells of the peripheral blood (287, 380) , which appear in the fibrous cup and in lipid-rich areas of human and experimentally-induced atherosclerotic plaques (381) (382) (383) (384) .Indeed, bone marrow provides inflammatory cells (lymphocytes and monocytes that become foam cells) and myofibroblast/myointimal cells, whose balance affects plaque stability (385, 386).These precursor cells have been considered in other sections of this paper.In this order, bone-marrow-derived mesenchymal cells can serve as a new cell source of smooth muscle cells in vessel engineering (387).Likewise, repopulation of endothelium and medial smooth muscle cells from both circulating and adjacent ends of non-affected artery cells has been demonstrated in rat patent arterial segments devoid of mural cells (adventitial, smooth muscle and endothelial cells) by local application of glycerol ( Figure 9A ) (42).The morphologic events in the early stages of cellular recruitment is reminiscent of those occurring in granulation (Fig.8A, HE, x120 ) and subsequently in the media layer (ML) and in the intimal thickening (IT). (Fig.8B , HE, x120) L: Arterial lumen.Microscopic image of microvessel penetration from adventitial microcirculation crossing the arterial medial layer (arrows) and reaching the intimal thickening (Fig.8C, HE, x160) .In Fig.8D (HE, x160) 3 H-labelled cells are observed in a microvessel penetrating the media layer and in cells of the intimal thickening.Using a contrast technique, microvessels penetrating arterial media layer are clearly observed (arrows) in stereoscopic images (Figs.8E-8F, x60) in transillumination images (Figs.8G and 8H, x120) and in series of microscopic images (Figs.8I and 8J, HE x160). tissue, with the following steps: a) reendothelialization ( Figure 9A ), apparently from adjacent ends of non-affected artery; b) presence of monocytes between endothelium and internal elastic lamina ( Figure 9B ); c) migration towards the media layer of monocytes and endothelial cells, crossing the elastic internal lamina fenestrations ( Figure  9C) ; d) formation of vascular channels with endothelial and mural cells in the innermost area of the media layer with continuity between arterial lumen endothelial cells and those in tunnelized structures ( Figure 9D ); e) involution of the newly-formed vascular channels, presenting platelets and red cells in their lumens ( Figure 9E ) and, simultaneously, proliferation of spindle cells, which finally repopulate the arterial media layer acquiring smooth muscle cell phenotype ( Figure 9F ).
ASC, RTGT and tumor stroma
The tumor stroma is a major factor influencing the growth and progression of cancer (388), including survival, migration, proliferation, invasion and metastasis.This tissue microenvironment is a complex and dynamic structure with similar characteristics, biological markers and components to RTGT, as well as with the same origin.These similarities also include induction of angiogenesis and stromal acquisition of the myofibroblast phenotype.Indeed, as occurs with RTGT, the tumor stroma population of cells consists of vascular elements (endothelium and pericytes), fibroblast-myofibroblasts and macrophages, with variable association of other inflammatory cells, arranged in a modified extracellular matrix (388-395).
As with RTGT, in tumor stroma growth intervene interactions between parenchymal (tumoral) cells and activated stromal cells, as well as several cellular and extracellular matrix molecules.Unlike normal connective tissue, which behaves as an antiprogressive environment of the neoplasia, the tumor stroma after tumor-like genetic lesions (396) (397) (398) acquires an active role in cancer progression with paracrine-acting factors.Thus, the tumor stroma provides physical architecture and blood supply (oxygen and nutrients), removes metabolic and biological waste and contributes growth factors, cytokines and extracellular matrix proteins, including adhesion proteins and proteases (394, (399) (400) (401) (402) (403) .For instance, macrophages, fibroblasts and endothelial cells express and secrete metalloproteinases (404) , which hydrolyze collagen, laminin, fibronectin and vitronectin (402, 405) .Actively recruited tumor-associated macrophages release V-G factor stimulators of angiogenesis (VEGF, HGF, MMP2, IL-8) as well as hypoxia-induced transcription factors.An enhancing role of tumor-associated myofibroblasts, facilitating the invasiveness of colon tumors, has been demonstrated by means of co-injection of activated fibroblasts and tumor cells (406) .The difference between tumor fibroblastmyofibroblasts and activated fibroblasts in RTGT is that tumor fibroblast-myofibroblasts change their phenotype and do not undergo apoptosis and elimination, remaining perpetually activated.The origin of tumor fibroblasts may be tissue-resident pericytes and fibroblasts (407) , bone marrow-derived mesenchymal cells (394, (408) (409) (410) (411) , fibrocytes (289, 410) or parenchymal and local cancer cell transdifferentiation (412) .Endosialin, a marker of mesenchymal stem cells, is expressed by tumor-associated myofibroblasts and pericytes (206, 207) (See above).CD34+ fibrocytes, which act as antigen presenting cells during carcinoma invasion, lose CD34 positivity expression for a gain of alpha-SMA expression (myofibroblast characteristic), contributing to the stroma tumor and to tumor escape from host immune control (289) .Mesenchymal stem cells from post-natal bone marrow are considered as an emerging tool for cellmediated gene therapy in several pathologic processes, including cancer therapy.Indeed, the homing of mesenchymal cells is favored in sites of active tumorigenesis, and these cells may be used as cell carriers for delivering anticancer factors (cytokines, interferons, replicable adenovirus, pro-drugs, among others) (413) .
12.OVERVIEW AND CLINICAL PROMISE
The extensive cellular plasticity of the principal cellular components in RTGT (local and circulating bone marrow derived progenitor cells), supported by so many different lines of evidence (Table 1) , is reasonably based, but relatively recent and some of the different capabilities of being precursor or descendent cells are not very defined.Therefore, further research is needed to confirm which of these proposed precursor cells are genuine pluripotential stem cells or which are only capable of expressing different properties and functional roles.
In all likelihood, these precursor cells reside in virtually all postnatal tissues and organs (414) and, in our opinion, the perivascular niche, with pericyte-like cells, including pericytes, homing cells from the bone marrow (fibrocytes and MSC) and perivascular fibroblasts, is the most solid hypothesis, now emerging (29, 37, 183-205, 208-215, 370, 415-421) .In this hypothesis (Figure 10 ), the perivascular region (with pericyte-like cells) is the niche of progenitor cells and the substrate of regulatory mechanisms.Indeed, pericyte-like cells, originate newpericytes, fibroblast-myofibroblasts (and related cells) and some subsets of macrophages.The regulatory mechanisms include: a) regulation of quiescent and angiogenic stages of blood vessels (cell-cell contacts and soluble factors produced by pericytes and EC), b) mesenchymal cell proliferation and differentiation control, and c) interactions between transmigrating cells (e.g.monocytes) and perivascular niche resident cells.
This hypothesis is difficult to confirm owing to the following: a) the heterogenous cellular population in a perivascular location with like-morphology (416); b) the need to identify the descendent cells in a location far from the niche (415, 422) ; c) the cells in the putative niche express several molecular markers, none of which is general or specific; and d) the markers are not continually expressed in the pericytic niche and descendent cells.This variable expression depends on species, location, diverse characteristics, functional state (422), distinct overlapping populations, and the quiescent or angiogenic stage of blood vessels (423) .There is even controversy among laboratories.Other procedures may be required in addition The mesenchymal stem cells isolated from various tissues and involved in RTGT (with innate ability to home to sites of tissue repair) are a therapeutic promise, which will increase when their lineage, full functional differentiation capacity and requirements for favoring cell renewal over differentiation during expansio in cultures is better understand (paradox between "in vitro" promise and "in vivo" efficacy -424).Clinical applications could involve the following (394, 395, 424) : 1) to engineer different tissues both "ex vivo" and "in vivo", such us cartilage (e.g.joint, nose, ear and trachea), bone (e.g.craneofacial and long bone defects) and myocardium (acute myocardial infarction), 2) to produce growth factors (e.g.member of the BMP family), proteins (e.g.protein deficiency disordershemophilias), collagen and trophic factors, 3) to induce angiogenesis and inhibit apoptosis, 4) to form "guiding strands" to promote direct growth of new axons during central nervous system or spinal cord injury, 5) to provide stromal support for transplanted cells (e.g.bone marrow transplants), and 6) to modify the tumor associated stroma and/or use as delivery vehicles for anti-cancer therapies.In this way, the future strategies include (394, 395) : a) modification of the genetically altered tumor stroma mesenchymal stem and descendent cells (unlike homeostatic RTGT cells, they might initiate and/or enhance tumor growth); b) use of mesenchymal stem cells as cellular delivery vehicles of antitumor agents (specific tropism of mesenchymal stem cells that survive and proliferate inside the tumor and that may act as a "mini pump", e.g., active and passive immunotherapy, therapeutic gene products, interferon β (394) (See above); c) actions to alter the expression of some cell surface receptors and to inhibit tumor promoting interactions, targeting one or multiple molecules (growth factors, growth factor receptors, adhesion molecules and enzymes -e.g., recombinant humanized anti-VEGF mab Bevacizumab and anti-CD105 antibody-); d) modulation of the tumor microenvironment by eliminating the stromal cells; and e) interference with the remodelling of the extracellular matrix (e.g.inhibitors of proteases -MMPS-). 
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